The Hepatitis C virus infects nearly 170 million people worldwide, and is the major cause of hepatitis and liver cancer. The current treatment is a therapy with pegylated interferon and ribavirin, which has severe side effects. Recent addition of HCV NS3/4A protease inhibitors to this therapy has improved HCV treatments, but the severe side effects and rapid emergence of drug resistance limit the effectiveness of this therapy. Therefore, new HCV therapies must be developed that are effective against a broader spectrum of resistant viral variants and HCV genotypes. This project followed the multi-step synthesis of a new variant of the MK-5172 inhibitor, evaluated the synthesis plan, and provided the UMass Medical School with a new inhibitor to test activity against NS3/4A protease variants.

• This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.

Creator

• Koumbaros, Evangelos Konstantinos

Contributors

• Jahangir, Muhammad

Publisher

• Worcester Polytechnic Institute

Identifier

• E-project-042513-122748

Advisor

• Heilman, Destin

Year

• 2013

Sponsor

• University of Massachusetts Medical Center, Worcester Massachusetts
• Akbar Ali

Date created

• 2013-04-25

Resource type

• Major Qualifying Project

Major

• Chemistry

Rights statement

• In Copyright